WW adds compounded GLP-1, expanding accessibility og weight loss medications

WeightWatchers announced the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions that are underpinned by the comprehensive, science-backed, behavioral and lifestyle support that has helped millions of people reach and sustain their weight goals. “At WeightWatchers, we have always combined proven science and personalized support to help our members achieve meaningful, lasting results. With the addition of compounded semaglutide, we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Tara Comonte, Interim CEO of WeightWatchers. “This launch is the culmination of extensive research and rigorous work by our team to ensure that we are offering the highest quality care – reaffirming the trust we’ve built over six decades as the leader in weight management.”